| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8750823 | Respiratory Investigation | 2017 | 8 Pages |
Abstract
Although this was a small retrospective study, its findings showed that S-1 and etoposide may be relatively safe options for the treatment of patients with lung cancer and concomitant ILD.
Keywords
CTD-ILDPPFEUIPNSIPVinorelbineHRCTCBDCAS-1IIPVP-16PTXECoGDIPRB-ILDrespiratory bronchiolitis-interstitial lung diseaseVNRPEMDTXIPFLIPDAD95% CIPFsILDEtoposideprogression-free survivalSCLCInterstitial lung diseaseacute exacerbationhigh-resolution computed tomographyDiffuse alveolar damageDocetaxelLung cancerNSCLCSmall cell lung cancerNon-small cell lung cancereastern cooperative oncology groupChemotherapy95% confidence intervalPleuroparenchymal fibroelastosisidiopathic pulmonary fibrosishazard ratioPerformance statusPaclitaxelPemetrexedLymphoid interstitial pneumonianon-specific interstitial pneumoniaIdiopathic interstitial pneumoniaUsual interstitial pneumoniaDesquamative interstitial pneumoniaCarboplatin
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
Authors
Soji MD, PhD, Masaki MD, PhD, Toshifumi MD, PhD, Atsuro MD, Kenji MD, Satoshi MD, PhD, Yuko MD, PhD, Hisatsugu MD,PhD, Hiroshi MD, PhD, Masahiko MD, PhD, Fumitaka MD, PhD, Yasuhiko MD, PhD,